ICOSLG and arthritic joint disease: ICOSL−/− or B cell-specific ICOSL−/− mice have markedly inhibited development of proteoglycan-induced arthritis, with notable reductions in TFH and GC B cells, IL-21 production, and proteoglycan-specific IgG antibody responses (113).